Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference

Press release

Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference

Will participate also in the following events:

•      Sachs Conference – BioPharma Obesity Innovation Forum

•      The BIO@JPM Week Conference

Paris (France) and Cambridge (Massachusetts, USA), 24 December 2024 – 7:00 AM CET – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces its participation in the inaugural BioPharma Obesity Innovation Forum (#Sachs_BOIF) on January 11, 2025, in San Francisco, as well as in the BIO@JPM Week conference during the 43rd annual JP Morgan Healthcare Conference, taking place from January 13 to 16, 2025, also in San Francisco.

The JP Morgan Healthcare Conference is the largest global healthcare event, bringing together industry leaders, innovative biotech companies, technology developers, and investors from the international financial community.

The BioPharma Obesity Innovation Forum, launching its first edition, will convene over 100 innovative companies, research organizations, and investors to address the challenges and advancements in obesity treatments. Biophytis will present on January 11 at 1:50 PM to highlight its strategic positioning in the obesity domain, provide an update on its development program and outline its key milestones for 2025.

Additionally, Biophytis will participate in the BIO@JPM Week conference to enhance interactions with pharmaceutical partners and investors.

* * * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. 

Disclaimer

This press release contains forward-looking statements.  Forward-looking statements include all statements that are not historical facts.  In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could,"

"seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these

                                                                                                                                                                1

words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.  However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts Biophytis 

Investor relations

Investors@biophytis.com

To schedule 1x1 Investor meetings in January 2025 in San Francisco:  Pascal Nigen: pnigen@alphabronzellc.com  - +1 (917) 385-2160.

Médias

Antoine Denry : antoine.denry@taddeo.fr – +33 6 18 07 83 27

Inès de Mandiargues : ines.demandiargues@taddeo.fr – 06 16 16 51 78

                                                                                                                                                                2